Kymera Therapeutics

kymeratx.com →

+8%

est. 2Y upside i

HealthcareIPO

Rank

#1867

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: Medium

Kymera offers high-risk, high-reward equity as a job candidate.

Last updated: July 3, 2026

Bull (20%)+100%

Positive Phase 2b data for KT-621 leads to accelerated path to market or major partnership, doubling valuation to ~$18.8B.

Base (40%)+20%

Steady progress and successful enrollment, valuation grows modestly to ~$11.3B.

Bear (40%)-50%

Trial failure or significant regulatory setback, valuation halves to ~$4.7B, common stock still has recovery after preference.

Est. time to liquidity~2.0 years

Preference Stack Risk

high

Funding Intensity

18%

Total funding of $1.7B represents 18.1% of current valuation, creating a high preference overhang.

Dilution Risk

low

Recent $692M offering provides ample runway; no immediate need for raise.

Secondary Liquidity

active

Company is publicly traded, providing daily liquidity for vested shares.

Questions to Ask at the Interview

Strategic questions based on Kymera Therapeutics's data — designed to show you've done your homework.

  • 1

    “How does Kymera's platform differentiate from Arvinas' PROTAC technology?”

  • 2

    “What is the market opportunity for KT-621 versus Dupixent?”

  • 3

    “How would you assess the risk of dilution given the company's cash runway?”

Community

Valuation Sentiment

Our model estimates +8% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.